Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

2020 Journal of the National Comprehensive Cancer Network 1,589 citations

Abstract

Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.

Keywords

MedicineOncologyBreast cancerClinical OncologyInternal medicineCancerClinical PracticeMetastatic breast cancerSystemic therapyStage (stratigraphy)GynecologyFamily medicine

MeSH Terms

Breast NeoplasmsClinical Decision-MakingDisease ManagementDisease SusceptibilityFemaleHumansNeoplasm MetastasisNeoplasm StagingRecurrence

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
18
Issue
4
Pages
452-478
Citations
1589
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1589
OpenAlex
27
Influential
665
CrossRef

Cite This

William J. Gradishar, Benjamin O. Anderson, Jame Abraham et al. (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network , 18 (4) , 452-478. https://doi.org/10.6004/jnccn.2020.0016

Identifiers

DOI
10.6004/jnccn.2020.0016
PMID
32259783

Data Quality

Data completeness: 86%